Myocardial Infarction (MI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

• Publication date: December 2011

Myocardial Infarction (MI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Summary GlobalData, the industry analysis specialist, has released its new report, “Myocardial Infarction (MI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Myocardial Infarction Therapeutics market. The report identifies the key trends s...

Myocardial Infarction (MI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Myocardial Infarction (MI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Myocardial Infarction Therapeutics market. The report identifies the key trends shaping and driving the global Myocardial Infarction Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Myocardial Infarction Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Myocardial Infarction Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Myocardial Infarction Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Myocardial Infarction Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Myocardial Infarction Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Myocardial Infarction Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Myocardial Infarction Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Myocardial Infarction Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Myocardial Infarction Therapeutics market landscape? – Identify, understand and capitalize.

Global Therapy Industry

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Myocardial Infarction (MI) Therapeutics - Introduction 7
2.1 Overview 7
2.2 MI classification based on myocardial necrosis in a clinical setting 8
2.3 MI classification based on ECG findings (clinical diagnosis) 8
2.4 Epidemiology 9
2.5 Etiology 9
2.6 Symptoms 10
2.7 Diagnosis 11
2.7.1 12-lead ECG 11
2.7.2 Biomarkers 12
2.7.3 Imaging Techniques 13
2.8 Treatment Algorithm of MI 13
2.8.1 Treatment for the Symptoms of MI - 13
2.8.2 Treatment for the Cause of MI 14
2.8.3 Primary and Secondary Prevention (Prophylaxis) 17
2.8.4 Other Treatment Options 18
2.9 GlobalData Pipeline Report Guide 19
3 MI Therapeutics - Market Characterization 20
3.1 Overview 20
3.2 MI Therapeutics Market Size (2005-2010) - Global 21
3.3 MI Therapeutics Market Forecast (2010-2018) - Global 22
3.4 MI Therapeutics Market Size (2005-2010) - The US 23
3.5 MI Therapeutics Market Forecast (2010-2018) - The US 24
3.6 MI Therapeutics Market Size (2005-2010) - France 25
3.7 MI Therapeutics Market Forecast (2010-2018) - France 26
3.8 MI Therapeutics Market Size (2005-2010) - Germany 27
3.9 MI Therapeutics Market Forecast (2010-2018) - Germany 28
3.10 MI Therapeutics Market Size (2005-2010) - Italy 29
3.11 MI Therapeutics Market Forecast (2010-2018) - Italy 30
3.12 MI Therapeutics Market Size (2005-2010) - Spain 31
3.13 MI Therapeutics Market Forecast (2010-2018) - Spain 32
3.14 MI Therapeutics Market Size (2005-2010) - The UK 33
3.15 MI Therapeutics Market Forecast (2010-2018) - Global 34
3.16 MI Therapeutics Market Size (2005-2010) - Japan 35
3.17 MI Therapeutics Market Forecast (2010-2018) - Japan 36
3.18 Drivers and Barriers for the MI Therapeutics Market 37
3.18.1 Drivers for the MI Therapeutics Market 37
3.18.2 Barriers for the MI Therapeutics Market 38
3.19 Opportunity and Unmet Need 38
3.20 Key Takeaway 40
4 MI Therapeutics - Competitive Assessment 41
4.1 Overview 41
4.2 Strategic Competitor Assessment 41
4.3 Product Profile for the Major Marketed Products in the MI Therapeutics Market 42
4.3.1 Nitrates 42
4.3.2 Beta-adrenergic Receptor Blockers (Beta Blockers) 43
4.3.3 Calcium Channel Blockers 43
4.3.4 Angiotensin Converting Enzyme Inhibitor (ACE inhibitors) 44
4.3.5 Statins 44
4.3.6 Glycoprotein IIb/ IIIa inhibitor 46
4.3.7 Lovenox (enoxaparin sodium injection) 49
4.3.8 Plavix/ Iscover (clopidogrel bisulfate) 51
4.3.9 Effient/ Efient (prasugrel) 52
4.3.10 Brilinta/Brilique (ticagrelor) 54
4.4 Key Takeaway 56
5 MI Therapeutics - Pipeline Assessment 57
5.1 Overview 57
5.2 Strategic Pipeline Assessment 57
5.3 MI Therapeutics Market - Promising Drugs under Clinical Development 61
5.4 Molecule Profile for Promising Drugs Under Clinical Development 62
5.4.1 A-002 (varespladib methyl) 62
5.4.2 Darapladib (SB-480848) 63
5.4.3 Xarelto (rivaroxaban) 64
5.4.4 Otamixaban 65
5.4.5 Elinogrel 65
5.4.6 Cangrelor 66
5.5 MI Therapeutics Market - Clinical Pipeline by Mechanism of Action 68
5.5.1 MI Therapeutics - Phase III Clinical Pipeline 70
5.5.2 MI Therapeutics - Phase II Clinical Pipeline 71
5.5.3 MI Therapeutics - Phase I Clinical Pipeline 72
5.5.4 MI Therapeutics - Discovery and Preclinical Pipeline 73
5.6 Key Takeaway 73
6 MI Therapeutics - Clinical Trials Mapping 74
6.1 Clinical Trials by Region/ Country (the US, EU5 & Japan) 74
6.2 Clinical Trials by Phase of Clinical Development 75
6.3 Clinical Trials by Trial Status 76
6.4 Clinical Trials by Sponsors 77
6.5 Brief Profiles of the Top 10 Companies Participating in Clinical Trials 79
7 MI Therapeutics - Strategic Assessment 80
7.1 Key Events Impacting the Future Market 80
7.2 Future Market Competition Scenario 81
8 MI Therapeutics - Future Players 83
8.1 Introduction 83
8.1.1 GlaxoSmithKline Plc 83
8.1.2 Anthera Pharmaceuticals 85
8.1.3 Novartis A G 85
8.1.4 Sanofi 86
8.1.5 Johnson & Johnson 87
8.1.6 Bayer AG 88
8.1.7 The Medicines Company 90
8.1.8 Merck and Co. Inc. 91
8.1.9 Portola Pharmaceuticals Inc. 92
8.1.10 Capricor Inc. 93
8.1.11 Tabular Presentation Details of Other Companies in the Pipeline 94
8.2 Key Takeaway 100
9 MI Therapeutics - Licensing and Partnership Deals 101
10 MI Therapeutics - Appendix 108
10.1 Definitions 108
10.2 Acronyms 108
10.3 Methodology 109
10.3.1 Coverage 109
10.3.2 Secondary Research 110
10.3.3 Forecasting 110
10.3.4 Primary Research 112
10.3.5 Expert Panel Validation 113
10.4 Contact Us 113
10.5 Disclaimer 113
10.6 Bibliography 113

List of Tables

Table 1: Biochemical Cardiac Markers of the Evaluation and Management of Patients with Suspected MI but Without ST-Segment Elevation on 12-Lead ECG 12
Table 2: Recommendations for Diagnosis and Risk Stratification 13
Table 3: Antiplatelet Medications 14
Table 4: Glycoprotein IIb/ IIIa Inhibitors 15
Table 5: The Goals of Fibrinolysis 16
Table 6: Pharmacotherapy for MI (STEMI and NSTEMI) 17
Table 7: MI Therapeutics Market, Global, Revenue ($m), 2005-2010 21
Table 8: MI Therapeutics Market, Global, Forecast ($m), 2010-2018 22
Table 9: MI Therapeutics Market, The US, Forecast ($m), 2005-2010 23
Table 10: MI Therapeutics Market, The US, Forecast ($m), 2010-2018 24
Table 11: MI Therapeutics Market, France, Revenue ($m), 2005-2010 25
Table 12: MI Therapeutics Market, France, Forecast ($m), 2010-2018 26
Table 13: MI Therapeutics Market, Germany, Revenue ($m), 2005-2010 27
Table 14: MI Therapeutics Market, Germany, Forecast ($m), 2010-2018 28
Table 15: MI Therapeutics Market, Italy, Revenue ($m), 2005-2010 29
Table 16: MI Therapeutics Market, Italy, Forecast ($m), 2010-2018 30
Table 17: MI Therapeutics Market, Spain, Revenue ($m), 2005-2010 31
Table 18: MI Therapeutics Market, Spain, Forecast ($m), 2010-2018 32
Table 19: MI Therapeutics Market, The UK, Revenue ($m), 2005-2010 33
Table 20: MI Therapeutics Market, The UK, Forecast ($m), 2010-2018 34
Table 21: MI Therapeutics Market, Japan, Revenue ($m), 2005-2010 35
Table 22: MI Therapeutics Market, Japan, Forecast ($m), 2010-2018 36
Table 23: Major Marketed Product Comparison in MI Therapeutics Market, 2011 55
Table 24: Comparison of P2Y12 Inhibitors 55
Table 25: P2Y12 Clinical Studies 56
Table 26: MI Therapeutics - Most Promising Drugs Under Clinical Development, 2010 61
Table 27: MI Therapeutics - Phase III Clinical Pipeline, 2011 70
Table 28: MI Therapeutics - Phase II Clinical Pipeline, 2011 71
Table 29: MI Therapeutics - Phase I Clinical Pipeline, 2011 72
Table 30: MI Therapeutics - Discovery and Preclinical Pipeline, 2011 73
Table 31: MI Therapeutics, Global, Clinical Trials, 2011 74
Table 32: MI Therapeutics, Global, Clinical Trials by Phase, 2011 75
Table 33: MI Therapeutics, Global, Clinical Trials by Status of Development, 2011 76
Table 34: MI Therapeutics, Global, Prominent Sponsors, 2011 78
Table 35: MI Therapeutics, Global, Top Ten Companies by Phase, 2011 79
Table 36: GlaxoSmithKline - Pipeline Products 84
Table 37: Anthera Pharmaceuticals Company - Pipeline Products 85
Table 38: Novartis A G Company - Pipeline Products 86
Table 39: Sanofi - Pipeline Products 87
Table 40: Johnson and Johnson Company - Pipeline Products 88
Table 41: Bayer AG - Pipeline Products 89
Table 42: The Medicines Company - Pipeline Products 91
Table 43: Merck & Co. Inc. - Pipeline Products 92
Table 44: Portola Pharmaceuticals - Pipeline Products 93
Table 45: Capricor Inc. - Pipeline Products 93
Table 46: Other Companies in Pipeline, MI Therapeutics, 2011 94
Table 47: MI Therapeutics, Global, Deals, 2011 101

List of Figures

Figure 1: Spectrum of ACS 7
Figure 2: Understanding ACS 8
Figure 3: Plaque Formation and Atherosclerosis 10
Figure 4: Investigation and Treatment Algorithm 11
Figure 5: MI Therapeutics Market, Global, Revenue ($m), 2005-2010 21
Figure 6: MI Therapeutics Market, Global, Forecast ($m), 2010-2018 22
Figure 7: MI Therapeutics Market, The US, Revenue ($m), 2005-2010 23
Figure 8: MI Therapeutics Market, The US, Forecast ($m), 2010-2018 24
Figure 9: MI Therapeutics Market, France, Revenue ($m), 2005-2010 25
Figure 10: MI Therapeutics Market, France, Forecast ($m), 2010-2018 26
Figure 11: MI Therapeutics Market, Germany, Revenue ($m), 2005-2010 27
Figure 12: MI Therapeutics Market, Germany, Forecast ($m), 2010-2018 28
Figure 13: MI Therapeutics Market, Italy, Revenue ($m), 2005-2010 29
Figure 14: MI Therapeutics Market, Italy, Forecast ($m), 2010-2018 30
Figure 15: MI Therapeutics Market, Spain, Revenue ($m), 2005-2010 31
Figure 16: MI Therapeutics Market, Spain, Forecast ($m), 2010-2018 32
Figure 17: MI Therapeutics Market, The UK, Revenue ($m), 2005-2010 33
Figure 18: MI Therapeutics Market, The UK, Forecast ($m), 2010-2018 34
Figure 19: MI Therapeutics Market, Japan, Revenue ($m), 2005-2010 35
Figure 20: MI Therapeutics Market, Japan, Forecast ($m), 2010-2018 36
Figure 21: Opportunity and Unmet Need in the MI Therapeutics Market, 2011 39
Figure 22: Strategic Competitor Assessment, 2011 42
Figure 23: MI Therapeutics - Distribution of Therapies 57
Figure 24: Mechanism of Action of Stem Cells For Cardiac Functional Improvement 58
Figure 25: Technology Trends Analytics Frame Work, 2011 60
Figure 26: Technology Trends Analytics Frame Work - Description, 2011 60
Figure 27: MI Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011 68
Figure 28: MI Therapeutics Market - Clinical Pipeline by Phase of Development, 2011 69
Figure 29: MI Therapeutics, Global, Clinical Trials by Country, 2011 74
Figure 30: MI Therapeutics, Global, Clinical Trials by Phase (%), 2011 75
Figure 31: MI Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 76
Figure 32: MI Therapeutics, Global, Overall Sponsors (%), 2011 77
Figure 33: MI Therapeutics, Global, Prominent Sponsors (%), 2011 78
Figure 34: MI Therapeutics, Global, Top Ten Companies by Phase, 2011 79
Figure 35: MI Therapeutics Market, Drivers and Barriers, 2011 80
Figure 36: Implications for Future Market Competition in the MI Therapeutics Market, 2011 81
Figure 37: MI Therapeutics Market - Clinical Pipeline by Company, 2011 83
Figure 38: GlobalData Market Forecasting Model 112

Companies mentioned
GlaxoSmithKline Plc
Anthera Pharmaceuticals
Novartis A G
Sanofi
Johnson & Johnson
Bayer AG
The Medicines Company
Merck and Co. Inc.
Portola Pharmaceuticals Inc.
Capricor Inc.